NASDAQ : RAPP
Rapport Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 25.05 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.48B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 36.85M | 30.31M | 22.12M | 8.18M | 1.37M |
| Research & Development | 94.79M | 94.79M | 60.94M | 28.00M | 4.49M |
| Operating Expenses | 131.64M | 125.10M | 83.06M | 36.18M | 5.85M |
| Operating Income | -153.52M | -125.10M | -83.06M | -36.18M | -5.85M |
| Interest Expense | -310.91K | ||||
| Interest & Investment Income | 16.36M | 13.62M | 12.14M | 2.53M | |
| EBT Excluding Unusual Items | -137.16M | -111.48M | -70.92M | -33.65M | -6.17M |
| Other Unusual Items | -7.39M | -1.12M | |||
| Pretax Income | -137.16M | -111.48M | -78.31M | -34.78M | -11.62M |
| Income Tax Expense | 10.00K | ||||
| Net Income | -137.16M | -111.48M | -78.31M | -34.79M | -11.62M |
| Net Income to Common | -137.16M | -111.48M | -78.31M | -34.79M | -11.62M |
| Shares Outstanding (Basic) | 44.93M | 38.93M | 20.74M | 1.51M | 777.21K |
| Shares Outstanding (Diluted) | 44.93M | 38.93M | 20.74M | 1.51M | 777.21K |
| EPS (Basic) | -3.05 | -2.86 | -3.78 | -23.10 | -14.95 |
| EPS (Diluted) | -3.05 | -2.86 | -3.78 | -23.10 | -14.95 |
| Free Cash Flow | -97.15M | -88.09M | -67.23M | -28.82M | -3.85M |
| Free Cash Flow Per Share | -2.16 | -2.26 | -3.24 | -19.14 | -4.95 |
| EBITDA | -152.56M | -124.08M | -82.22M | -36.07M | -5.84M |
| D&A For EBITDA | 960.00K | 1.02M | 839.00K | 112.00K | 16.36K |
| EBIT | -153.52M | -125.10M | -83.06M | -36.18M | -5.85M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.61M | 52.65M | 56.80M | 70.17M | 31.16M |
| Short-Term Investments | 372.46M | 437.89M | 248.47M | 77.31M | |
| Cash & Short-Term Investments | 436.08M | 490.54M | 305.28M | 147.48M | 31.16M |
| Prepaid Expenses | 10.28M | 7.82M | 4.42M | 1.50M | 109.00K |
| Restricted Cash | 105.00K | 105.00K | 105.00K | 85.00K | |
| Other Current Assets | 100.00K | 100.00K | 1.81M | ||
| Total Current Assets | 446.86M | 498.56M | 309.80M | 150.87M | 31.27M |
| Property, Plant & Equipment | 11.07M | 12.88M | 4.97M | 4.00M | 335.00K |
| Long-Term Deferred Charges | 35.00K | 300.00K | |||
| Other Long-Term Assets | 1.06M | 950.00K | 160.00K | 251.00K | |
| Total Assets | 458.98M | 512.43M | 314.93M | 155.42M | 31.60M |
| Accounts Payable | 2.80M | 4.19M | 1.95M | 2.50M | 1.45M |
| Accrued Expenses | 23.16M | 12.10M | 6.08M | 5.63M | 213.00K |
| Current Portion of Leases | 2.47M | 2.75M | 737.00K | 670.00K | |
| Total Current Liabilities | 28.42M | 19.05M | 8.77M | 8.80M | 1.66M |
| Long-Term Debt | 4.20M | 10.44M | |||
| Long-Term Leases | 7.63M | 8.73M | 739.00K | 1.48M | |
| Total Liabilities | 36.06M | 27.78M | 9.51M | 14.48M | 12.10M |
| Common Stock | 48.00K | 48.00K | 37.00K | 4.00K | 31.00K |
| Additional Paid-In Capital | 735.85M | 719.29M | 429.66M | 19.80M | 559.00K |
| Retained Earnings | -311.70M | -235.23M | -123.75M | -45.44M | -10.65M |
| Comprehensive Income & Other | -1.27M | 546.00K | -522.00K | 4.00K | |
| Total Common Equity | 422.93M | 484.65M | 305.43M | -25.63M | -10.06M |
| Shareholders' Equity | 422.93M | 484.65M | 305.43M | 140.94M | 19.50M |
| Total Liabilities & Equity | 458.98M | 512.43M | 314.93M | 155.42M | 31.60M |
| Total Debt | 10.11M | 11.48M | 1.48M | 6.35M | 10.44M |
| Net Cash (Debt) | 425.97M | 479.06M | 303.80M | 141.13M | 20.72M |
| Net Cash Per Share | 9.48 | 12.30 | 14.65 | 93.73 | 26.66 |
| Filing Date Shares Outstanding | 47.98M | 47.79M | 36.50M | 4.17M | 777.21K |
| Total Common Shares Outstanding | 47.96M | 47.77M | 36.58M | 4.17M | 777.21K |
| Working Capital | 418.43M | 479.51M | 301.04M | 142.07M | 29.61M |
| Book Value Per Share | 8.82 | 10.15 | 8.35 | -6.15 | -12.95 |
| Tangible Book Value | 422.93M | 484.65M | 305.43M | -25.63M | -10.06M |
| Tangible Book Value Per Share | 8.82 | 10.15 | 8.35 | -6.15 | -12.95 |
| Machinery | 4.18M | 4.54M | 3.78M | 1.76M | 295.00K |
| Construction In Progress | 118.00K | 430.00K | 26.00K | 55.00K | |
| Leasehold Improvements | 295.00K | 295.00K | 281.00K | 255.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -137.16M | -111.48M | -78.31M | -34.79M | -11.62M |
| Depreciation & Amortization | 960.00K | 1.02M | 839.00K | 112.00K | 16.36K |
| Asset Writedown & Restructuring Costs | 5.45M | ||||
| Loss (Gain) From Sale of Investments | -887.00K | -1.40M | -3.21M | -75.00K | |
| Stock-Based Compensation | 24.59M | 18.86M | 10.23M | 3.52M | 609.82K |
| Other Operating Activities | 2.31M | 2.03M | 8.03M | 1.39M | 379.64K |
| Change in Accounts Payable | -375.00K | 2.21M | -346.00K | 856.00K | 1.58M |
| Change in Other Net Operating Assets | 14.02M | 1.29M | -2.07M | 1.80M | 46.91K |
| Operating Cash Flow | -96.68M | -87.47M | -64.83M | -27.18M | -3.54M |
| Capital Expenditures | -467.00K | -616.00K | -2.40M | -1.64M | -309.82K |
| Sale (Purchase) of Intangibles | -5.45M | ||||
| Investment in Securities | -167.28M | -186.86M | -167.74M | -77.22M | |
| Investing Cash Flow | -167.56M | -187.47M | -170.14M | -78.86M | -5.76M |
| Total Debt Issued | 8.73M | ||||
| Net Debt Issued (Repaid) | 8.73M | ||||
| Issuance of Common Stock | 273.18M | 270.79M | 157.71M | 54.00K | 33.82K |
| Repurchase of Common Stock | -5.00K | -1.00K | -4.00K | ||
| Other Financing Activities | -391.00K | -134.00K | -111.27K | ||
| Financing Cash Flow | 272.79M | 270.79M | 221.62M | 145.14M | 43.29M |
| Net Cash Flow | 8.54M | -4.16M | -13.34M | 39.09M | 33.99M |
| Free Cash Flow | -97.15M | -88.09M | -67.23M | -28.82M | -3.85M |
| Free Cash Flow Per Share | -2.16 | -2.26 | -3.24 | -19.14 | -4.95 |
| Levered Free Cash Flow | -56.02M | -54.17M | -44.47M | -17.43M | |
| Unlevered Free Cash Flow | -56.02M | -54.17M | -44.47M | -17.43M | |
| Change in Working Capital | 13.35M | 3.50M | -2.42M | 2.65M | 1.62M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 1.49B | 1.45B | 648.87M | ||
| Enterprise Value | 1.06B | 944.88M | 329.86M | ||
| Last Close Price | 25.13 | 30.34 | 17.74 | ||
| PB Ratio | 2.85 | 2.98 | 2.12 | ||
| P/TBV Ratio | 3.52 | 2.98 | 2.12 | ||
| Debt / Equity Ratio | 0.02 | 0.02 | 0.01 | 0.04 | 0.54 |
| Net Debt / Equity Ratio | -1.01 | -0.99 | -0.99 | -1.00 | -1.06 |
| Net Debt / EBITDA Ratio | 2.79 | 3.86 | 3.69 | 3.91 | 3.55 |
| Net Debt / FCF Ratio | 4.38 | 5.44 | 4.52 | 4.90 | 5.39 |
| Quick Ratio | 15.35 | 25.75 | 34.82 | 16.75 | 18.74 |
| Current Ratio | 15.72 | 26.17 | 35.34 | 17.14 | 18.80 |
| Return on Equity (ROE) | -39.96% | -28.22% | -35.09% | -43.36% | |
| Return on Assets (ROA) | -25.78% | -18.90% | -22.07% | -24.18% | |
| Return on Capital Employed (ROCE) | -35.70% | -25.40% | -27.10% | -24.70% | -19.60% |
| Earnings Yield | -12.15% | -7.71% | -12.07% | ||
| FCF Yield | -6.53% | -6.09% | -10.36% | ||
| Buyback Yield / Dilution | -27.52% | -87.74% | -1,277.25% | -93.74% |